Cobratide injection vs pregabalin for moderate-to-severe acute herpes zoster neuralgia: A randomized, double-blind, double-dummy, active-controlled, multicenter exploratory trial
Journal of the American Academy of Dermatology · 2026
DOI: 10.1016/j.jaad.2026.06.062 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2026. Verfasst von Xuegang Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning Province, China. Hauptthemen laut MEDLINE: Pregabalin, Herpes Zoster, Analgesics, Neuralgia, Postherpetic. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Acute herpes zoster (HZ) neuralgia impairs quality of life and may progress to postherpetic neuralgia (PHN). Existing analgesics are often limited by adverse effects in older adults. OBJECTIVE: To evaluate Cobratide injection for moderate-to-severe acute HZ neuralgia and explore its potential effect on PHN incidence. METHODS: In this multicenter, randomized, double-blind, double-dummy, active-controlled exploratory trial, 80 patients aged 50-70 years were assigned 1:1 to intramuscular Cobratide injection or oral Pregabalin for 28 days. The primary endpoint was change in average Numeric Rating Scale (NRS) pain score from baseline to day 28. No formal power calculation was performed. RESULTS: At day 28, least-squares mean NRS reductions were 6.00 with Cobratide injection and 5.63 with Pregabalin (between-group difference, 0.37; P = .186). At week 12, PHN occurred in 0/27 and 3/27 evaluable patients, respectively (P = .236). Treatment-emergent adverse events occurred in 35.9% and 51.2% of patients, respectively. LIMITATIONS: Exploratory design, small sample size, and lack of systematic collection of zoster vaccination history and rash-onset timing limited inference. CONCLUSIONS: Cobratide injection showed a similar magnitude of pain reduction to Pregabalin, with a favorable tolerability signal. Larger adequately powered trials are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
- Department of Reconstructive and Plastic Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
- Department of Dermatology, Central Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning Province, China.
- Department of Dermatology, Wuhan NO.1 Hospital, Wuhan, China.
- Department of Dermatology, First Medical Centre of Chinese PLA General Hospital, Beijing, China.
- Department of Dermatology, Binzhou Medical University Hospital, Binzhou, China.
Zitieren
APA
Xu, X., Han, X., Li, X., Chen, L., Li, C., Ma, L., Ji, M., Zhang, Y., Chen, H., Wang, X., Wang, Q., & Gao, X. (2026). Cobratide injection vs pregabalin for moderate-to-severe acute herpes zoster neuralgia: A randomized, double-blind, double-dummy, active-controlled, multicenter exploratory trial. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.06.062
Vancouver
Xu X, Han X, Li X, Chen L, Li C, Ma L, et al. Cobratide injection vs pregabalin for moderate-to-severe acute herpes zoster neuralgia: A randomized, double-blind, double-dummy, active-controlled, multicenter exploratory trial. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.06.062
BibTeX
@article{Xu2026,
author = {Xu, Xuegang and Han, Xu and Li, Xiaodong and Chen, Liuqing and Li, Chengxin and Ma, Lei and Ji, Mingkai and Zhang, Yanhui and Chen, Hongxiang and Wang, Xiuli and Wang, Qiang and Gao, Xinghua},
title = {Cobratide injection vs pregabalin for moderate-to-severe acute herpes zoster neuralgia: A randomized, double-blind, double-dummy, active-controlled, multicenter exploratory trial},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2026.06.062}
}
EUVIMED